Coherus Oncology
CHRS | NASDAQ
$0.51
-$0.02 (-2.95%)
At close: Nov 16, 2026, 4:00 PM ET
$0.51
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:59 PM ET
-2.95%
(1D)No price chart data available for 1D timeframe.
Rating
34.5
Fundamentals Average
Market Sentiment Bearish
Moat None
Sector Rank #662/1021 (Top 65%)
Key Statistics
Market Data
Market Cap $78.18M
1D Range
0.48 0.53
52W Range
0.48 2.51
Valuation (TTM)
PE -0.53
PB 3.10
EV/EBITDA -0.45
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $6.00
Cash Flow
FCF Yield -222.2%
SBC Adj. FCF Yield -236.0%
SBC Impact -6.2%
Margins
Gross Margin 66.5%
Operating Margin -275.9%
FCF Margin -323.9%
Growth (CAGR)
Revenue 3Y | 5Y -36.7% |
-31.8%
Dil EPS 3Y | 5Y -49.0% |
37.8%
FCF 3Y | 5Y -51.4% |
13.8%
Returns
ROA -79.0%
ROE -239.6%
ROIC -180.1%
Financial Health
Net Cash
$14.08M
Current Ratio 1.47
Interest Coverage -15.52
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercial...
Sector Healthcare
Industry Biotechnology
Employees 144
IPO Date Nov 6, 2014
Website www.coherus.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 9, 2026
EPS
-$0.25
Miss -14.19%
YoY:
+24.24% REV
$14.27M
Miss -10.24%
YoY:
+23.36%Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$6.00
Upside
+1076.47%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CHRS